Connect with us

Press Release

Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers

Published

on

–News Direct–

By Jeremy Golden, Benzinga

Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.

Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.

Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.

Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.

Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.

CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.

Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.

CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).

When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:

1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;

2) Favorable changes in the trajectory of tumor progression;

3) Decreased tumor size of target lesions in most patients; and

4) Reduced size of uninjected tumor lesions.

The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.

As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.

When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.

In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.

In the upcoming year, Candel plans to announce data readouts for the following:

1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;

2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;

3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.

Featured photo by National Cancer Institute on Unsplash.

Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.

Contact Details

Aljanae Reynolds

+1 617-916-5445

areynolds@wheelhouselsa.com

Company Website

https://www.candeltx.com/

View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267

Candel Therapeutics

comtex tracking

COMTEX_453480918/2655/2024-06-07T08:28:02

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

2027 Federal Withholding Tax Tables Announced by American Tax Service

Published

on

American Tax Service has published an updated guide to the 2027 federal withholding tax tables, explaining how employers calculate federal income tax deductions from employee paychecks using IRS withholding methods and Form W-4 information.

Estero, FL, United States, 21st Nov 2026 – American Tax Service has updated its educational coverage of the 2027 federal tax withholding tables following the Internal Revenue Service’s release of a draft Publication 15-T, Federal Income Tax Withholding Methods.

2027 Federal Withholding Tax Tables Announced by American Tax Service

The updated resource, 2027 Federal Tax Withholding Tables, explains how employers, payroll departments, employees, and retirees can prepare for changes to federal income tax withholding during the 2027 tax year.

The IRS posted its draft 2027 Publication 15-T on November 12, 2026. The document is an early release draft, not the final publication. The IRS also provided the 2027 withholding tables in an accompanying Excel file rather than incorporating them into the initial draft PDF.

IRS Releases Preliminary 2027 Payroll Withholding Guidance

Publication 15-T explains the methods employers and other payers use to calculate federal income tax withholding from wages and certain periodic pension and annuity payments.

The publication covers two primary calculation methods:

  • Wage Bracket Method for payroll systems using wage ranges.
  • Percentage Method for calculating withholding using adjusted wages and applicable rates.

Employers use these methods along with employee information provided on Form W-4. The correct calculation depends on filing status, payroll frequency, wages, and any additional withholding adjustments.

The IRS cautions that draft publications are subject to change. Employers should review the final 2027 Publication 15-T before relying on the updated procedures for payroll processing.

2027 Tax Brackets and Payroll Withholding

The 2027 federal tax brackets have also been announced, with seven marginal income tax rates continuing at 10%, 12%, 22%, 24%, 32%, 35%, and 37%.

The IRS increased the income thresholds for the 2027 tax year to account for inflation. The standard deduction for married couples filing jointly increases to $33,200, while the standard deduction for single taxpayers increases to $16,600.

American Tax Service provides additional information about the 2027 federal tax brackets and the 2027 federal tax tables for married filing jointly.

These annual tax adjustments are important because withholding calculations are designed to account for the applicable tax structure and deductions.

Form W-4 and Employee Withholding Adjustments

Form W-4, Employee’s Withholding Certificate, provides employers with information used to calculate federal income tax withholding.

Employees can review their withholding after major financial changes, including marriage, divorce, a new job, a salary increase, additional income, or retirement.

Married employees with two incomes should pay particular attention to their withholding elections. If both spouses work, incorrect W-4 information can result in insufficient federal income tax withholding throughout the year.

American Tax Service also maintains a guide to the 2026 federal withholding tax tables, which remain useful for understanding the current payroll withholding system.

Payroll Preparation for the 2027 Tax Year

Employers should prepare to update payroll systems when the final 2027 withholding guidance becomes available. Businesses that calculate payroll manually should also review the appropriate IRS wage bracket and percentage methods.

Federal income tax withholding is separate from Social Security and Medicare payroll taxes. Employers must continue to calculate these payroll taxes under their applicable requirements.

Employees and retirees can also review the 2026 federal tax tables to better understand how taxable income and filing status affect their federal income tax calculations.

About American Tax Service

American Tax Service provides educational tax information covering federal income tax brackets, withholding tables, IRS forms, deductions, tax credits, retirement income, and tax filing requirements. Its resources are designed to help taxpayers, employees, retirees, and employers better understand federal tax rules and prepare for upcoming filing and payroll changes.

Media Contact

Organization: American Tax Service

Contact Person: Frank Ellis

Website: https://americantaxservice.org/

Email: Send Email

Address: 20020 Barletta Lane

City: Estero

State: FL

Country: United States

Release id: 50944

View source version on King Newswire:
2027 Federal Withholding Tax Tables Announced by American Tax Service

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

A New Approach to Retirement Planning – Jim Capuano’s Newly Released Book Helps Americans Protect Their Retirement Savings

Published

on

United States, 21st Nov 2026 – Financial services professional and IRMAA-Certified Planner Jim Capuano has released his book, The Great American Retirement Myth. The new book is an eye-opening retirement planning guide that debunks common myths, demystifies industry jargon, and equips readers with the tools and techniques to protect and grow their wealth in retirement. It offers an in-depth look at how assets should be structured, taxed, and distributed.

Paperback Expert

The Great American Retirement Myth is a comprehensive book that exposes common financial planning practices that leave retirees with hefty tax bills, lower income, and less spending power than their savings suggest. It helps readers understand that the people they trust to manage their money often follow industry practices that generate more profit for their firms and don’t necessarily work in the retiree’s favor. By simplifying complex financial concepts and equipping readers with the knowledge to make informed decisions, the book helps Americans from all walks of life understand the shifting retirement landscape, navigate the system, and ultimately protect and grow their assets throughout retirement. Whether it’s retirement savings, Medicare, or Social Security, the book invites readers to reconsider familiar advice and approach financial planning with a clearer understanding of their options.

The Great American Retirement Myth by Jim Capuano

Jim Capuano is an IRMAA-Certified Planner who has applied his expertise to clients in the financial services industry for nearly two decades. He is passionate about helping individuals, families, and organizations keep what they earn and grow it. He founded and leads The Integrity Life Brokerage. He spent years working with consumers in the retail sector and with financial advisors in the wholesale market, gaining experience on both sides of the financial services industry.

With his thought-provoking new book, he invites American retirees to broaden their understanding of retirement-related financial decisions by learning how the industry operates on the inside. After many years of developing and refining his methods, his work now focuses primarily on insurance-based financial strategies and retirement planning.

Jim Capuano, IRMAACP™, is available for interviews.

Title: The Great American Retirement Myth

Author: Jim Capuano, IRMAACP™

Contact: Michael DeLon 

Company:  Paperback Expert 

Email: press@PaperbackExpert.com  

Phone Number:  (501) 404-8690

About Jim Capuano: https://theintegritylb.com/our-team

Availability: Amazon.com

Book Preview: https://www.amazon.com/dp/B0HPMMVXG2

Media Contact

Organization: Paperback Expert

Contact Person: Michael DeLon

Website: https://paperbackexpert.com/

Email: Send Email

Contact Number: +15014048690

Country: United States

Release id: 50999

View source version on King Newswire:
A New Approach to Retirement Planning – Jim Capuano’s Newly Released Book Helps Americans Protect Their Retirement Savings

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Face the IRS with Confidence Daniel Cotts’s Newly Released Book Reveals Complete Tax Resolution Strategies

Published

on

United States, 21st Nov 2026 – Tax attorney and tax resolution specialist Daniel Cotts has released his book, The IRS Bouncer: A Survivor—Your Last Line of Defense Against the IRS. The new book is a valuable financial guide that helps individuals and small businesses achieve complete tax resolution and put measures in place to avoid future IRS trouble. Beyond professional challenges, the book also examines the immense personal cost of tax debt.

Paperback Expert

The IRS Bouncer is an empowering book that equips readers with the knowledge, confidence, tools, and strategies to face the IRS and negotiate resolutions that work in taxpayers’ favor. It brings together practical explanations of IRS enforcement procedures, legal resolution strategies, and real-world client experiences to address problems that affect individuals and businesses nationwide. It not only takes a deep dive into installment agreements, offers in compromise, partial payment installment agreements, and more, but also highlights powerful options beyond conventional repayment arrangements. The author also shares his story of overcoming personal adversity after a near-fatal accident left him in a coma, connecting his experience with the challenges faced by taxpayers dealing with mounting liabilities, intimidating correspondence, and aggressive collection measures.

The IRS Bouncer by Daniel Cotts

Daniel Cotts is a seasoned tax attorney passionate about helping American families, businesses, and individuals achieve complete tax resolution. As the founder of Cotts Law, he is known for resolving serious tax disputes and guiding clients through audits, liens, levies, and garnishments. With a Juris Doctor and a Master of Accountancy, he is also licensed to practice before the United States Tax Court, giving him a competitive advantage and enabling him to understand the American tax system from the inside out.

After graduating from Southern Methodist University with a Master of Laws in Taxation, he proactively educates the public about tax issues and their legal rights when dealing with the IRS. Through his new book, he helps readers understand their options, choose the right legal representation, and regain financial control after resolution.

Daniel Cotts is available for interviews.

Title: The IRS Bouncer: A Survivor—Your Last Line of Defense Against the IRS

Author: Daniel Cotts, Tax Attorney

Contact: Michael DeLon 

Company:  Paperback Expert 

Email: press@PaperbackExpert.com  

Phone Number:  (501) 404-8690

About Daniel Cotts: https://cottslaw.com/about

Availability: Amazon.com

Book Preview: https://www.amazon.com/dp/B0HM8J296D

Media Contact

Organization: Paperback Expert

Contact Person: Michael DeLon

Website: https://paperbackexpert.com/

Email: Send Email

Contact Number: +15014048690

Country: United States

Release id: 51000

View source version on King Newswire:
Face the IRS with Confidence Daniel Cotts’s Newly Released Book Reveals Complete Tax Resolution Strategies

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST